Eflornithine/sulindac

Drug Profile

Eflornithine/sulindac

Alternative Names: CPP-1X/sul; CPP-1X/sulindac; CPP1-x/sulindac; MDL 71782; RMI 71782; TP 09

Latest Information Update: 16 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sanofi-aventis; University of Arizona
  • Developer Cancer Prevention Pharmaceuticals; Genzyme Corporation; National Cancer Institute (USA); World Health Organization
  • Class Antineoplastics; Basic amino acids; Diamino amino acids; Indenes; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Ornithine decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Trypanosomiasis
  • Phase III Colorectal cancer; Familial adenomatous polyposis
  • Discontinued Basal cell cancer; Bladder cancer; Prostate cancer; Sporadic adenomas; Squamous cell cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 04 Apr 2016 Cancer Prevention Pharmaceuticals completes enrolment in its phase III trial for Familial adenomatous polyposis in USA, Canada, Germany, the Netherlands, Belgium, Spain and United Kingdom
  • 11 Jan 2016 Cancer Prevention Pharmaceuticals enter into an option and collaboration agreement with Sucampo Pharmaceuticals for development of Eflorornithine/sulindac in Familial Adenomatous Polyposis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top